Medication info
Wonsaltan Plus EF Tablets

Wonsaltan Plus EF Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Dae Won Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200607922 · Notified 2006.09.18

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.
Child dose
○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Dae Won Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used additionally to effectively lower and control blood pressure in patients with hypertension who have difficulty managing blood pressure with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.

Child dose

○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This drug can cause serious harm to the fetus during pregnancy; therefore, treatment should be immediately discontinued if pregnancy is confirmed. This drug should not be administered to patients with certain diseases or conditions, such as anuria, severe liver dysfunction, severe renal dysfunction, and a history of specific allergies. When administering this drug, caution is required for patients with various conditions such as hypotension, impaired renal function, electrolyte imbalance, liver dysfunction, hyperuricemia, diabetes, and cerebrovascular disease. Since this drug lowers blood pressure, dizziness or drowsiness may occur at the beginning of treatment or when increasing the dose; caution is advised when driving or operating machinery. Regular monitoring of renal function and electrolyte status through blood tests is necessary during treatment, with particular attention to changes in potassium levels. This drug can interact with other medications, so patients should consult their doctor before taking it with potassium supplements, potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs, lithium, etc. The hydrochlorothiazide component can make the skin sensitive to sunlight, increasing the risk of skin cancer with long-term use; hence, sun exposure should be minimized, and skin changes should be carefully observed. Potential adverse reactions during treatment may include dizziness, cough, abdominal pain, edema, skin rashes, etc., and if symptoms are severe, consultation with a physician is necessary. Safety and efficacy have not been established for children and adolescents, so use in this age group is not recommended. Elderly patients may experience adverse reactions more frequently, thus greater caution is warranted, and their physical condition should be closely monitored. Pregnant and breastfeeding women should avoid taking this drug, and if breastfeeding, it is advisable to either stop breastfeeding or discontinue medication. Overdose may result in symptoms such as hypotension and tachycardia, and immediate medical attention should be sought for appropriate management. This drug should be stored out of reach of children and sealed in its original container.

Side effects

  • Abdominal pain
  • swelling
  • palpitations
  • back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 140 more
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurogenic hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • nasal bleeding
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • hair loss
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • eye pain
  • burning sensation
  • conjunctivitis
  • decreased vision
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequency
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • salivary gland inflammation
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • agitation
  • renal failure
  • renal function impairment
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • hypotension
  • tachycardia
  • hypokalemia
  • hypochloremia
  • hyponatremia
  • xerostomia
  • thirst
  • somnolence
  • drowsiness
  • agitation
  • seizure
  • myalgia
  • muscle fatigue
  • decreased urine output
  • nausea
  • vomiting
  • vasculitis
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to light and should be stored in a special container that prevents light exposure. Additionally, it should be stored at room temperature between 1°C to 30°C, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.